The Feds Just Moved Medical Marijuana to Schedule III: Here's What It Actually Means

For more than five decades, federal law has lumped marijuana in with heroin. As of this week, that's no longer the whole story. On Thursday, April 23, 2026, Acting Attorney General Todd Blanche announced that the Department of Justice and the Drug Enforcement Administration had signed afinal order moving certain marijuana products from Schedule I of the Controlled Substances Act to Schedule III. The effective date is April 22, 2026.

If you've been following federal cannabis policy for the last fifteen or so years, you know that progress has generally moved at roughly the speed of a stoned sloth. This time it's actually a seismic shift, but whether it's the "full federal legalization" a lot of folks have been hoping for is a different question entirely, and one worth answering in plain language.

So let's get into it. Here's what happened, what it actually changes, and what to keep an eye on between now and the summer.

What Actually Happened

The short version: the federal government now formally recognizes that marijuana has an accepted medical use. That's a structural shift, not a symbolic one.

The move carries out a December 18, 2025 executive order from President Trump titled Increasing Medical Marijuana and Cannabidiol Research, which directed the Justice Department to complete rescheduling as expeditiously as the law allows. Acting AG Blanche used a provision of the Controlled Substances Act (21 U.S.C. 811(d)(1)) that lets the attorney general reschedule a drug to comply with United States treaty obligations under the UN Single Convention on Narcotic Drugs. That's a faster legal lane than the typical multi-year rulemaking process.

Here's what changed in plain English:

• FDA-approved drug products that contain marijuana are now Schedule III substances.
• Marijuana and marijuana products covered by a qualifying state medical marijuana license are now Schedule III substances.
• Everything else, including bulk marijuana, unlicensed crops, recreational marijuana, and any marijuana that hasn't yet been incorporated into an FDA-approved product or state medical license, stays in Schedule I.

DEA is alsoholding a separate administrative hearing starting June 29, 2026 to consider whether to reschedule the rest of it. More on that at the end.

What Schedule III Actually Means

The Controlled Substances Act sorts drugs into five schedules based on their medical use and potential for abuse. Schedule I is the most restrictive and is reserved for substances the federal government considers to have "no currently accepted medical use." Heroin, LSD, and ecstasy all live there. For 56 years, marijuana has been right next to them on the list.

Schedule III is a very different neighborhood. It includes prescription drugs like ketamine, anabolic steroids, Tylenol with codeine, and testosterone. These are substances the government recognizes as having legitimate medical applications, even if they require oversight to prevent misuse.

Moving marijuana into Schedule III is the first formal federal acknowledgement that it has "accepted medical use." That's not cultural approval or a cheerful federal endorsement, but it is the government officially admitting, on paper, something that76 percent of doctors have been saying for years. Better late than never.

What's Covered, and What Definitely Isn't

This is where things get a little weird, so bear with us.

The order creates a two-tiered system where the same cannabis plant is treated as two different things depending on the license that covers it. In an interview with CNN, Colorado cannabis attorney Rachel Gillette put it plainly, saying they have "bifurcated one plant into two different schedules," which she called very odd.

What's now in Schedule III:

• Marijuana and marijuana products subject to a qualifying state medical marijuana license
• Marijuana extracts held under the same license framework
• Naturally derived delta-9-THC when it's part of an FDA-approved drug or a state-licensed medical product
• FDA-approved drugs containing marijuana, such as Epidiolex

What remains in Schedule I:

• Recreational (adult-use) marijuana, even in states where it's legal
• Bulk marijuana that hasn't been incorporated into a finished product
• Unlicensed marijuana crops
• Synthetically derived cannabinoids, including delta-10-THC

Hemp (defined as cannabis with no more than 0.3 percent delta-9-THC on a dry-weight basis) was already excluded from the definition of marijuana under federal law, so this order doesn't change anything there.

If you run a business or hold a license that straddles both medical and adult-use markets, this split is going to take some adjusting to. For most consumers, the practical picture is easier to navigate.

What This Means If You're a Patient

If you're an existing medical marijuana patient, here's the most important thing to know: your current medical card and physician recommendation still work exactly the same way they did before. State programs are unchanged. Your dispensary will keep operating the way it always has, and you can keep accessing your medicine without disruption.

What's new is the federal backdrop. For the first time, the federal government formally acknowledges that your medicine has a recognized therapeutic purpose. That's a meaningful shift for anyone who has dealt with the awkwardness of using something their state approves but their federal government still technically treats as comparable to heroin.

One nuance that's not going away in the short term: the difference between a physician "recommendation" and a true federal "prescription." A formal prescription under federal law still requires the FDA to approve a specific product. State medical programs will continue to issue recommendations in most cases, not prescriptions. That said, Schedule III designation opens the door to a future where physicians could eventually prescribe specific cannabis-based medications, and where insurance could theoretically cover them. (If you're not sure whether you need a medical card in the first place,we've written about that too.)

On the tax side, patients who acquire medical marijuana under a qualifying prescription may now be eligible to claim it as a medical expense deduction on Schedule A of their federal return. The IRS is still working out the details, so don't go amending returns just yet.

What This Means for the Cannabis Industry

Here's the part the industry has been waiting on for more than a decade: state-licensed medical marijuana businesses are no longer subject to IRS Section 280E. That's the tax provision that blocked businesses selling Schedule I or II substances from deducting ordinary operating expenses or claiming tax credits, and it has been the single most punishing part of federal law for legal cannabis operators.

We here at Where's Weed will have a deeper dive on this in a follow-up article aimed at dispensary owners and industry operators, but here's the quick summary:

• Industry estimates shared by NPR suggest the effective tax burden for medical cannabis operators could drop from the 70 to 80 percent range down to something closer to 20 to 30 percent.
• Treasury and the IRS haveannounced they plan to issue formal guidance, including a transition rule that generally applies the change across the business's full taxable year containing the effective date.
• The order explicitly encourages the Treasury to consider retroactive relief for years the business was operating under a state medical license.
• DEA has established an expedited registration pathway, with a six-month target processing window for applications filed within the first 60 days of publication.
• State licensees will also be eligible to apply for import and export permits for the first time, opening access to international markets.

Operators running both adult-use and medical licenses will need to carefully segregate their activities, because Section 280E still applies to the adult-use side of the business.

Banking is still unsettled. Rescheduling alone doesn't automatically give cannabis businessesaccess to the banking system, though it narrows the legal risk picture in ways that may start moving things forward.

What This Means for Researchers

Schedule I has been the single biggest obstacle to serious scientific research on cannabis for decades. Universities and hospitals have worried that studying a Schedule I drug could jeopardize federal research funding. Researchers who wanted to study cannabis had to navigate a long list of DEA approvals and were often limited to a single federally approved source of research-grade marijuana that didn't reflect what patients were actually using.

Schedule III changes that math considerably. Research protocols involving the now-rescheduled products are substantially easier to get approved, and DEA-registered researchers can now source materials from state-licensed manufacturers without automatic liability concerns. The order explicitly protects researchers from adverse action based solely on obtaining cannabis from a state licensee.

The DOJ itself described this as one of the main points of the action, writing that it will "enable more targeted, rigorous research into marijuana's safety and efficacy." For an industry that has been running ahead of science for 30 years, that's probably the most under-the-radar piece of the whole announcement.

What This Means If You're Just a Regular Consumer

If you live in a recreational state and you've been buying weed at an adult-use shop, honestly, not much changes for you right now.

The order does not legalize adult-use marijuana. It does not decriminalize possession. It does not expunge prior cannabis convictions. And recreational cannabis products remain Schedule I substances under federal law. Your local dispensary experience is going to look about the same tomorrow as it did last week.

The bigger question, whether all marijuana (adult-use included) should be moved to Schedule III, is being sent to a separate DEA administrative hearing. That hearing begins on June 29, 2026 and is scheduled to conclude no later than July 15, 2026. If that process results in full rescheduling, the picture for adult-use operators and consumers changes substantially. For now, though, it's a wait-and-see situation.

What's Coming Next

A few things worth keeping tabs on in the coming months:

• The June 29 DEA administrative hearing on whether to reschedule all marijuana to Schedule III, not just the medical segment. The hearing is expected to conclude by mid-July 2026, though any litigation could extend the timeline.
• IRS and Treasury guidance on exactly how 280E relief will be applied, including any retroactive component. This is the piece that will determine how much real money flows back into the medical cannabis industry, and how quickly.
• Legal challenges. Smart Approaches to Marijuana, an anti-legalization advocacy group, has already announced it will take legal action to block the order. Expect at least one lawsuit, possibly more.
• DEA registration processing for state-licensed medical operators seeking federal authorization to manufacture, distribute, and dispense. Applications filed in the first 60 days after Federal Register publication get an expedited six-month review.

The Bottom Line

The April 22 rescheduling is the biggest shift in federal cannabis policy in over fifty years. It's not full legalization, it's not broad decriminalization, and it doesn't clean up every contradiction that state-versus-federal law has been grinding on for decades. What it does is officially acknowledge that marijuana has a legitimate medical purpose under federal law, and that acknowledgment comes with real consequences for how medical cannabis businesses are taxed, how researchers can work with the plant, and how patients are treated under federal law.

If you're a patient, your card still works and your state program is still operational. If you're a recreational consumer, your short-term picture is basically unchanged. If you're watching the industry, the real test comes at the June 29 hearing " where the question of broader rescheduling gets its formal airing.

Plenty more to come on this one. We'll keep you posted.